The life cycle of tertiary lymphoid structures in pancreatic cancer—a window of opportunity for immunotherapy
-
By
-
Yimin Chen
-
Yi Xiao
-
Taochun Zhang
-
Xinbo Wang
-
May 28, 2026
-
Clinical Scorecard: The Developmental Stages of Tertiary Lymphoid Structures in Pancreatic Cancer: A Potential Target for Immunotherapeutic Strategies
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Tertiary lymphoid structures (TLS) influence tumor immune microenvironment and prognosis. [Source needed] |
| Target Population | |
| Care Setting | |
Key Highlights
- TLS presence is linked to improved prognosis in pancreatic cancer. [Source needed]
- The tumor microenvironment is characterized by low immunogenicity and strong immunosuppression.
- Recent studies suggest that TLS can enhance the efficacy of chemotherapy. [Source needed]
- There is a translational disconnect between preclinical models and clinical outcomes regarding TLS.
- Understanding TLS dynamics may lead to innovative therapeutic strategies. [Source needed]
Guideline-Based Recommendations
Diagnosis
- Identification and detection of TLS in the tumor microenvironment. [Source needed]
Management
- Combination of systemic chemotherapy and local chemokines to enhance TLS formation. [Source needed]
Monitoring & Follow-up
- Evaluate TLS evolution and its impact on treatment response. [Source needed]
Risks
- Limited efficacy of immunotherapy in PDAC due to immunosuppressive tumor microenvironment.
Patient & Prescribing Data
Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC).
Chemotherapy combined with immunotherapeutic strategies may improve outcomes.
Clinical Best Practices
- Consider TLS dynamics when designing treatment protocols for PDAC. [Source needed]
- Monitor the impact of therapies on TLS evolution and patient outcomes. [Source needed]
Related Resources & Content
